Page 3 - Karen Aiach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Karen aiach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Karen Aiach Today - Breaking & Trending Today

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , France General , United Kingdom , Karen Aiach , Raymond Wang , Foundation Of Caring Lysosomal Storage Disorder Program , European Union , Sarepta Therapeutics Inc , Founder Chairman , Chief Executive Officer , Caring Lysosomal Storage Disorder Program , Rare Pediatric Disease , Casimir Trials , Sarepta Therapeutics , French Autorit , Des March , French Markets Authorities , Durant Des Aulnois , Financial Officer ,

Gene Therapy Candidate Fast Tracked for GM1 Gangliosidosis

Gene Therapy Candidate Fast Tracked for GM1 Gangliosidosis
neurologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neurologyadvisor.com Daily Mail and Mail on Sunday newspapers.

Karen Aiach , Drug Administration , Fast Track , Orphan Drug , வேகமாக டிராக் , ஆர்ஃபந் மருந்து ,

Gene Therapy Candidate Fast Tracked for GM1 Gangliosidosis


Gene Therapy Candidate Fast Tracked for GM1 Gangliosidosis
The treatment is administered as a single dose intracisternal injection. (Credit: Getty Images.)
The Food and Drug Administration (FDA) has granted Fast Track designation to LYS-GM101 for the treatment of GM1 gangliosidosis.
GM1 gangliosidosis is a rare inherited lysosomal storage disorder caused by deficient beta-galactosidase activity related to a mutation in the GLB1 gene. This enzyme mutation results in an accumulation of GM1-ganglioside which leads to progressive neurodegeneration. 
LYS-GM101 is a gene therapy designed to replace the gene mutation and restore the production of the beta-galactosidase enzyme. The investigational therapy uses an adeno-associated viral vector to deliver a functional copy of the GLB1 gene to the CNS. ....

Karen Aiach , Drug Administration , Fast Track , Orphan Drug , வேகமாக டிராக் , ஆர்ஃபந் மருந்து ,